Delayed Reaction: BioMarin Rises On Pegvaliase Data

BioMarin Pharmaceutical Inc. has bounced back from a stock price slump that occurred after it reported that pegvaliase, the company's second therapy to treat phenylketonuria (PKU), met the primary endpoint in a Phase III clinical trial, but failed to meet a key secondary endpoint.

BioMarin fell 3.4% on March 21, but jumped 6.7% to close at $83.43 per share on March 22 after investors apparently spent more time reviewing data for pegvaliase, a product...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

02 Jun 2025

• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

02 Jun 2025

• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

02 Jun 2025

• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.